Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
| Last: | $374.045 |
|---|---|
| Change Percent: | 2.31% |
| Open: | $368.27 |
| Close: | $365.585 |
| High: | $374.57 |
| Low: | $366.53 |
| Volume: | 853,910 |
| Last Trade Date Time: | 03/09/2026 12:45:58 pm |
| Market Cap: | $198,734,368,843 |
|---|---|
| Float: | 533,095,864 |
| Insiders Ownership: | 0.02% |
| Institutions: | 1871 |
| Short Percent: | N/A |
| Industry: | Pharmaceuticals |
| Sector: | Healthcare |
| Website: | https://www.amgen.com |
| Country: | US |
| City: | Thousand Oaks |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Amgen Inc. (NASDAQ: AMGN).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.
Get instant news alerts to your mobile device as soon as the news hits the wire. Simply add a stock symbol to your portfolio and our service will alert you anytime there is news.
